MentionFox
Home › Stakes › Quince Therapeutics, Inc.
5%+ stakes · Schedule 13D and 13G

Quince Therapeutics, Inc.: 5%+ holders

Who has reported owning 5% or more of Quince Therapeutics, Inc., from Schedule 13D and 13G filings: each holder's stake as filed, the timeline, and the purpose each 13D states, quoted.

At 5% or more6
Filings11
Latest filing2026-08-14

Quince Therapeutics, Inc. has 11 Schedule 13D or 13G filings on record since 2025-08-14. 6 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

HolderPercentSharesLatestEvent date
Group One Trading LLC10.7%5,942,906SCHEDULE 13G, 2026-03-052026-02-28
Balyasny Asset Management L.P.9.99%97,699SCHEDULE 13G, 2026-08-142026-06-30
Cormorant Asset Management, LP9.99%108,029SCHEDULE 13G, 2026-08-142026-06-30
Ikarian Capital, LLC9%91,789SCHEDULE 13G, 2026-08-142026-06-30
Integrated Core Strategies (US) LLC7.2%1,403,580SCHEDULE 13G, 2026-06-102026-06-04
Squadron Master Fund LP5.6%55,173SCHEDULE 13G, 2026-08-042026-07-28
Nantahala Capital Management, LLC0%0SCHEDULE 13G/A, 2026-08-142026-06-30
Genextra S.p.A.0%0SCHEDULE 13G/A, 2025-10-302025-07-07

Timeline

FiledHolderPercentFiling
2025-08-14Nantahala Capital Management, LLC9.99%SCHEDULE 13G
2025-10-30Genextra S.p.A.0%SCHEDULE 13G/A
2025-11-14Nantahala Capital Management, LLC9.99%SCHEDULE 13G/A
2026-03-05Group One Trading LLC10.7%SCHEDULE 13G
2026-05-15Nantahala Capital Management, LLC7.52%SCHEDULE 13G/A
2026-06-10Integrated Core Strategies (US) LLC7.2%SCHEDULE 13G
2026-08-04Squadron Master Fund LP5.6%SCHEDULE 13G
2026-08-14Nantahala Capital Management, LLC0%SCHEDULE 13G/A
2026-08-14Balyasny Asset Management L.P.9.99%SCHEDULE 13G
2026-08-14Cormorant Asset Management, LP9.99%SCHEDULE 13G
2026-08-14Ikarian Capital, LLC9%SCHEDULE 13G

Tools for this story

Each opens in a new tab, filled in for Quince Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

Cite this page

Permanent URL: https://mentionfox.com/stakes/quince-therapeutics
Last updated 2026-09-27
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Quince Therapeutics, Inc. 5%+ holders: 6 at 5% or more, largest Group One Trading LLC 10.7%. MentionFox, 2026-09-27. https://mentionfox.com/stakes/quince-therapeutics